1. Home
  2. BYND vs ALT Comparison

BYND vs ALT Comparison

Compare BYND & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Meat Inc.

BYND

Beyond Meat Inc.

HOLD

Current Price

$0.71

Market Cap

346.2M

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.46

Market Cap

415.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYND
ALT
Founded
2009
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
346.2M
415.3M
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
BYND
ALT
Price
$0.71
$3.46
Analyst Decision
Sell
Strong Buy
Analyst Count
7
6
Target Price
$1.70
$17.67
AVG Volume (30 Days)
30.2M
2.9M
Earning Date
05-06-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
53.80
25.37
EPS
N/A
N/A
Revenue
$326,452,000.00
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$756,308.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$0.50
$2.91
52 Week High
$7.69
$7.73

Technical Indicators

Market Signals
Indicator
BYND
ALT
Relative Strength Index (RSI) 43.28 33.89
Support Level $0.67 $3.40
Resistance Level $0.82 $4.25
Average True Range (ATR) 0.06 0.23
MACD -0.00 -0.04
Stochastic Oscillator 9.80 10.40

Price Performance

Historical Comparison
BYND
ALT

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: